- Merger to create NASDAQ-listed, clinical-stage biopharmaceutical company focused on advancing Disc Medicine’s portfolio of hematology programs
- Combined company is expected to have approximately $175 million of cash or cash equivalents at close, including approximately $53.5 million from a concurrent financing restricted to Disc’s existing investors, and which is expected to provide funding into 2025
- Transaction will fund multiple clinical studies, including clinical trials of bitopertin for erythropoietic porphyrias, DISC-0974 for anemia of myelofibrosis, and DISC-0974 for anemia of chronic kidney disease
- Companies will host a joint webcast today, August 10, 2022 at 8:00 a.m. Eastern Time
Texas Billionaire Timothy Dunn Backed US Oil & Gas Player Explores $10B Sale
CrownRock is reportedly in the early stages of preparing for a potential sale, with insiders indicating that the company's valuation could surpass $10 billion, including its outstanding debt.
